2.6 million for novel heart valve prostheses
The novel heart valve system developed by the medical technology company is presenting an aortic valve, which is introduced via a minimally invasive catheter. It can be repositioned if necessary by the operator following a check on how it is functioning or be removed. This new development represents a significant improvement on methods already available. Also in patients with a poor health status, this gentle operation method can be used. In these patients often no valve replacement can be performed. The preclinical testing has been successfully completed. They demonstrated the safe implantation and new positioning of the valve prostheses in an animal model. Now the CEOs Dr. Wolfgang Goetz and Hou-Sen Lim and the existing and new investors are expecting confirmation of the excellent results in the following clinical trials.
Transcatheter Technologies GmbH was founded in 2009 in Regensburg. It develops novel medical technology products, which can reduce the trauma in surgical interventions on the heart. In 2011 a first round of finance enabled the further development of aortic valve prostheses. The innovation of this Regensburg company makes the opening of the thorax unnecessary, a complicated and difficult
operation for patients. There is an enormous treatment potential for a growing number of patients with age-related cardiovascular disease. With approximately 350,000 aortic valves implanted worldwide currently, this corresponds to a market of more than 700 million Euros.
For more information see: